Supercritical Fluids Processing of Recombinant Human Growth Hormone

Document identifier: oai:DiVA.org:ltu-7615
Access full text here:10.1081/DDC-200047368
Publication year: 2005
Relevant Sustainable Development Goals (SDGs):

The SDG label(s) above have been assigned by OSDG.ai

Abstract:

The aim of the study was to investigate the feasibility of precipitating recombinant human growth hormone (hGH) from aqueous solutions using conventional and modified techniques of solution-enhanced dispersion (SEDS) by supercritical fluids. The study investigated the effect on hGH stability of adding isopropanol either as a cosolvent with the original aqueous protein solution (conventional process) or to the supercritical carbon dioxide before mixing with the aqueous protein solution (modified process). The influence of the addition of sucrose (with or without isopropanol) on the precipitation behavior and stability of the protein was also studied. Experiments were performed under various processing conditions (pressure 100-200 bars and temperature 40-50°C), and with various flow rates and solution compositions (CO2/isopropanol and protein solution). Bioanalytical characterization of the resulting powders involved spectrophotometry, sodium dodecyl sulfate-polycrylamide gel electrophoresis, reverse-phase high performance liquid chromatography (RP-HPLC), and size exclusion chromatography. Solid-state characterization was performed using differential scanning calorimetry, X-ray powder diffraction, scanning electron microscopy, and Karl Fischer techniques. Results showed that with both conventional and modified methods, under optimum processing conditions, the presence of sucrose in the solution decreased the destabilizing effects of the solvent and/or process on the structure of hGH. More hGH was dissolved from the precipitated powders containing sucrose than from those containing only isopropanol. Reverse-phase HPLC indicated that about 94% of the hGH was recovered in its native form. The proportion of dimers and oligomers was reduced in the presence of sucrose; about 92% of the soluble protein was present in monomer form under optimal conditions. The remaining undissolved protein was in monomeric form. The precipitated powders were amorphous, containing particulate aggregates in the size range 1-6 µm with 5-10% residual moisture content. In conclusion, hGH was successfully precipitated from aqueous solution using SEDS technology. The presence of sucrose in the protein solution promoted the precipitation of hGH and reduced aggregation and improved dissolution

Authors

Sitaram Velaga

Other publications >>

Johan Carlfors

Uppsala university, Department of Pharmacy
Other publications >>

Record metadata

Click to view metadata

	
    header: 
        identifier: oai:DiVA.org:ltu-7615
        datestamp: 2021-04-19T11:02:37Z
        setSpec: SwePub-ltu
    metadata: 
        mods: 
            @attributes: 
                version: 3.7
            recordInfo: 
                recordContentSource: ltu
                recordCreationDate: 2016-09-29
            identifier: 
                http://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-7615
                10.1081/DDC-200047368
                60250bc0-e8ca-11db-b9a9-000ea68e967b
            titleInfo: 
                @attributes: 
                    lang: eng
                title: Supercritical Fluids Processing of Recombinant Human Growth Hormone
            abstract: 
The aim of the study was to investigate the feasibility of precipitating recombinant human growth hormone (hGH) from aqueous solutions using conventional and modified techniques of solution-enhanced dispersion (SEDS) by supercritical fluids. The study investigated the effect on hGH stability of adding isopropanol either as a cosolvent with the original aqueous protein solution (conventional process) or to the supercritical carbon dioxide before mixing with the aqueous protein solution (modified process). The influence of the addition of sucrose (with or without isopropanol) on the precipitation behavior and stability of the protein was also studied. Experiments were performed under various processing conditions (pressure 100-200 bars and temperature 40-50°C) and with various flow rates and solution compositions (CO2/isopropanol and protein solution). Bioanalytical characterization of the resulting powders involved spectrophotometry sodium dodecyl sulfate-polycrylamide gel electrophoresis reverse-phase high performance liquid chromatography (RP-HPLC) and size exclusion chromatography. Solid-state characterization was performed using differential scanning calorimetry X-ray powder diffraction scanning electron microscopy and Karl Fischer techniques. Results showed that with both conventional and modified methods under optimum processing conditions the presence of sucrose in the solution decreased the destabilizing effects of the solvent and/or process on the structure of hGH. More hGH was dissolved from the precipitated powders containing sucrose than from those containing only isopropanol. Reverse-phase HPLC indicated that about 94% of the hGH was recovered in its native form. The proportion of dimers and oligomers was reduced in the presence of sucrose; about 92% of the soluble protein was present in monomer form under optimal conditions. The remaining undissolved protein was in monomeric form. The precipitated powders were amorphous containing particulate aggregates in the size range 1-6 µm with 5-10% residual moisture content. In conclusion hGH was successfully precipitated from aqueous solution using SEDS technology. The presence of sucrose in the protein solution promoted the precipitation of hGH and reduced aggregation and improved dissolution

            language: 
                languageTerm: eng
            genre: 
                publication/journal-article
                ref
            note: 
                Published
                2
                Upprättat; 2005; 20070412 (andbra)
            name: 
                    @attributes: 
                        type: personal
                        authority: ltu
                    namePart: 
                        Velaga
                        Sitaram
                    role: 
                        roleTerm: aut
                    nameIdentifier: 
                        sitvel
                        0000-0002-0654-5410
                    @attributes: 
                        type: personal
                    namePart: 
                        Carlfors
                        Johan
                    role: 
                        roleTerm: aut
                    affiliation: Uppsala university Department of Pharmacy
            originInfo: 
                dateIssued: 2005
            relatedItem: 
                @attributes: 
                    type: host
                titleInfo: 
                    title: Drug Development and Industrial Pharmacy
                identifier: 
                    0363-9045
                    1520-5762
                part: 
                    detail: 
                            @attributes: 
                                type: volume
                            number: 31
                            @attributes: 
                                type: issue
                            number: 2
                    extent: 
                        start: 135
                        end: 49
            physicalDescription: 
                form: print
            typeOfResource: text